Share this article:

I have an expression that I like to use when describing a drug's fall from grace—I call it going from panacea to panic. This description suits the latest media focus on the anti-viral flu drug, Tamiflu.          

Tamiflu was wrongly touted as a potential cure-all for the bird flu craze just two years ago, and its manufacturer, Roche, was ramping up to increase its supply at a time when H5N1 bird flu was responsible for the deaths of millions of birds in Asia but only a rare human being, and hadn't come to the US at all—and still hasn't. Nevertheless, two years ago people were begging their doctors for prescriptions of this perishable and expensive drug, without any idea how or even if they were going to use it.                                                                                                      

At the same time, Tamiflu has real uses against the yearly human flu that kills hundreds of thousands around the globe. Many millions of doses have been prescribed around the world, especially in Japan. It is not surprising that rare side effects such as behavior abnormalities and anxiety that may be associated with Tamiflu have been reported in a country where the drug is prescribed so freely.                                                                                                                                                     

It is a difficult decision whether or not to warn against a rare side effect for a drug that is used so often, and perhaps over-prescribed. On the other hand, Tamiflu clearly has an important role. None of the four anti-flu drugs currently on the market are cures—they are all intended to decrease the length and severity of symptoms in patients. But these drugs when used judiciously can save lives—because there are many patients with chronic illnesses who are not strong enough to survive the full force of the flu.                                                                                                                                                

And of the four anti-flu drugs available, Tamiflu, a neuraminidase inhibitor, has the least amount of drug resistance, and still appears to be the best tolerated.                                 

In the face of indiscriminate use of a drug, warnings may be prudent, as long as they don't convince people who really need the drug not to take it.

Marc Siegel, MD, is an internist and associate professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.